A diary of the thought process behind my investment decisions
Sold 1/2 of Amgen Position
I sold half my Amgen position. I remain bullish on the name. According to Goldman Sachs research, stocks typically outperform by about 2% in the week heading into a tender offer. The Amgen tender is December 7. With this move I have roughly reduced my net long exposure back to where it was before last week.